Results 71 to 80 of about 25,328 (173)

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI‐Platinum Therapy (WJOG14120L)

Cancer Science, EarlyView.
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka, Keita Mori, Nobuhisa Ishikawa, Hiroaki Kanemura, Koichi Azuma, Yukihiro Toi, Hiroshi Handa, Yosuke Tamura, Hiroaki Akamatsu, Haruko Daga, Masafumi Yamaguchi, Teppei Yamaguchi, Yuki Sato, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Takayasu Kurata   +15 more
wiley   +1 more source

Potential Role of Liver Transplantation for Child–Pugh Class A Hepatocellular Carcinoma: Prognosis and Medical Expenditure in Japan—A Retrospective Single‐Center Study

Hepatology Research, EarlyView.
Among patients with CP‐A HCC initially within the Japan criteria, some lose oncological eligibility for LT before hepatic decompensation. Further studies are needed to identify baseline factors associated with poor outcomes and to evaluate their relevance to future LT candidacy.
Akihiro Seki, Tomoyoshi Chiba, Shintaro Yagi, Rika Horii, Noboru Takata, Hiroki Nomura, Masaki Miyazawa, Tomoyuki Hayashi, Takeshi Terashima, Shinichi Nakanuma, Mitsuyoshi Okazaki, Satoshi Takada, Tatsuya Yamashita, Masao Honda, Hajime Takatori, Tetsuro Shimakami, Taro Yamashita   +16 more
wiley   +1 more source

Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury

Hepatology Research, EarlyView.
Patients with severe ICI‐induced liver injury are commonly treated with corticosteroids, but the optimal tapering strategy remains uncertain. In this study, a gradual corticosteroid tapering strategy based partly on Japanese clinical practice for autoimmune hepatitis was associated with a low rate of relapse and enabled many patients to safely resume ...
Naoto Soma, Yoshihito Uchida, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Yukinori Imai, Suguru Mizuno, Satoshi Mochida   +7 more
wiley   +1 more source

Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer

BMC Cancer
Introduction The standard treatment for stage III non-small cell lung cancer (NSCLC) is platinum-based concurrent chemoradiotherapy (CCRT), followed by durvalumab (anti-programmed death ligand-1 antibody) maintenance therapy. Biomarkers related to immune-
Ryo Yano, Takaaki Tokito, Kenta Murotani, Daiki Murata, Shingo Tsuneyoshi, Hidenobu Ishii, Koichi Azuma, Tomoaki Hoshino   +7 more
doaj   +1 more source

Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression

Histopathology, EarlyView.
Hybrid grading systems significantly improve progression‐risk stratification in non‐invasive papillary urothelial carcinoma compared with the WHO 2004/2016 binary classification, with most benefit achieved by a Hybrid 3‐Tier framework. These findings support the existence of a histomorphological continuum of progression risk within the conventional ...
Jane K Nguyen, Marcello P Toscano, Jianbo Li, Sean R Williamson, Christopher G Przybycin, Chia‐Sui Kao, Jonathan L Myles, Kristýna Pivovarčíková, Marián Švajdler, Marek Brousil, Mohamed Eltemamy, Laura Bukavina, Venkatesh Krishnamurthi, Christopher Weight, Rebecca A Campbell, Nima Almassi, Reza Alaghehbandan   +16 more
wiley   +1 more source

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim The optimal treatment strategy for patients with intermediate‐stage hepatocellular carcinoma beyond the up‐to‐seven criteria (Barcelona Clinic Liver Cancer B2) remains uncertain. Although transarterial chemoembolization has long been the standard of care, its efficacy is limited in this subgroup, and systemic therapies have ...
Keishi Ouchi, Masashi Ninomiya, Mio Tsuruoka, Jun Inoue, Atsushi Hiraoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Takayoshi Oikawa, Kei Endo, Tamami Abe, Masashi Fujita, Kazumichi Abe, Tomohiro Katsumi, Wataru Sato, Chikara Iino, Nobukazu Tanabe, Hiroshi Numao, Hiromasa Ohira, Hidekatsu Kuroda, Yoshiyuki Ueno, Atsushi Masamune   +22 more
wiley   +1 more source

Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis

JTO Clinical and Research Reports
Introduction: At the first interim analysis of the phase 3 ADRIATIC trial, durvalumab consolidation significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with limited-stage SCLC (LS-SCLC ...
Lixia Ma, MD, Qiming Wang, MD, Jian Fang, MD, Anhui Shi, MD, Lin Wu, MD, Shun Lu, MD, Zhengfei Zhu, MD, Yunpeng Liu, MD, Qifeng Wang, MD, Hao Jiang, MD, Xiaoling Li, MD, Mengzhao Wang, MD, Yuan Chen, MD, Hongda Lu, MD, Yuzhong Duan, MD, Rui Meng, MD, Liyan Jiang, MD, Lujun Zhao, MD, Wenbin Zhu, PhD, Yunru Chen, MD, Leah Szadkowski, MS, Yuka Olivo, MS, Suresh Senan, M.B.B.S., PhD   +22 more
doaj   +1 more source

Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes.
Yuichi Honma, Shigeo Shimose, Takanori Ito, Issei Saeki, Joji Tani, Takanori Matsuura, Tetsu Tomonari, Yasuto Takeuchi, Nobuhito Taniki, Kyo Sasaki, Ryu Sasaki, Takeshi Hatanaka, Satoru Kakizaki, Naoki Yoshioka, Takehito Naito, Mamiko Takeuchi, Tetsuya Yasunaka, Masahiro Sakata, Hideki Iwamoto, Tomotake Shirono, Satoshi Itano, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Yuki Kanayama, Hisamitsu Miyaaki, Sohji Nishina, Nobuhiro Nakamoto, Motoyuki Otsuka, Tetsuji Takayama, Yuzo Kodama, Hideki Kobara, Taro Takami, Hiroki Kawashima, Takumi Kawaguchi, Masaru Harada, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group   +36 more
wiley   +1 more source

Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives

Life
Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy.
Gyula Laszlo Fekete, Laszlo Barna Iantovics, Júlia Edit Fekete, Laszlo Fekete   +3 more
doaj   +1 more source

Optimal Stenting Strategy During Chemotherapy: Impact of Time to First Reintervention on Survival in Malignant Hilar Biliary Obstruction

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Advances in chemotherapy have increased survival in biliary tract cancer patients, and reports of the effectiveness of neoadjuvant therapy are emerging. Accordingly, developing optimal drainage strategies under chemotherapy is important.
Katsuhiko Sato, Minoru Shigekawa, Teppei Yoshioka, Kazuma Daiku, Syuhei Yamamoto, Yu Sato, Takahiro Kodama, Hayato Hikita, Tetsuo Takehara   +8 more
wiley   +1 more source